Skip to main content

Advertisement

Log in

Precision surgery for breast cancer: current trends and future perspectives

  • Letter to the Editor
  • Published:
Updates in Surgery Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Data availability

Not applicable.

References

  1. Boggi U (2023) Precision surgery. Updates Surg 75(1):3–5. https://doi.org/10.1007/s13304-022-01447-7

    Article  PubMed  Google Scholar 

  2. Franceschini G, Di Leone A, Natale M, Sanchez MA, Masett R (2018) Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer. Ann Ital Chir 89:290

    PubMed  Google Scholar 

  3. Fine RE, Gilmore RC, Dietz JR, Boolbol SK, Berry MP, Han LK, Kenler AS, Sabel M, Tomkovich KR, VanderWalde NA, Chen M, Columbus KS, Curcio LD, Feldman SM, Gold L, Hernandez L, Manahan ER, Seedman SA, Vaidya RP, Sevrukov AB, Aoun HD, Hicks RD, Simmons RM (2021) Cryoablation without excision for low-risk early-stage breast cancer: 3-year interim analysis of ipsilateral breast tumor recurrence in the ICE3 trial. Ann Surg Oncol 28(10):5525–5534. https://doi.org/10.1245/s10434-021-10501-4

    Article  PubMed  Google Scholar 

  4. Banys-Paluchowski M, Rubio IT, Ditsch N, Krug D, Gentilini OD, Kühn T (2023) Real de-escalation or escalation in disguise? Breast 4(69):249–257. https://doi.org/10.1016/j.breast.2023.03.001

    Article  Google Scholar 

  5. Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, Pijnappel RM, Bijker N, Rutgers EJ, Wesseling J (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—the LORD study. Eur J Cancer 51(12):1497–1510. https://doi.org/10.1016/j.ejca.2015.05.008

    Article  PubMed  Google Scholar 

  6. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Exceptional Responders Clinical Trials Group (2022) Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517–1524. https://doi.org/10.1016/S1470-2045(22)00613-1

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gianluca Franceschini.

Ethics declarations

Human and animals rights

Not applicable.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

All Authors provide this consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Franceschini, G., Scardina, L. & Masetti, R. Precision surgery for breast cancer: current trends and future perspectives. Updates Surg 75, 1369–1371 (2023). https://doi.org/10.1007/s13304-023-01569-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13304-023-01569-6

Navigation